Literature DB >> 21843643

The structure of NS-398 bound to cyclooxygenase-2.

Alex J Vecchio1, Michael G Malkowski.   

Abstract

The cyclooxygenases (COX-1 and COX-2) are membrane-associated, heme-containing homodimers that generate prostaglandin H(2) from arachidonic acid (AA) in the committed step of prostaglandin biogenesis and are the targets for nonsteroidal anti-inflammatory drugs (NSAIDs). N-(2-cyclohexyloxy-4-nitrophenyl) methanesulfonamide (NS-398) was the first in a series of isoform-selective drugs designed to preferentially inhibit COX-2, with the aim of ameliorating many of the toxic gastrointestinal side effects caused by conventional NSAID inhibition. We determined the X-ray crystal structure of murine COX-2 in complex with NS-398 utilizing synchrotron radiation to 3.0A resolution. NS-398 binds in the cyclooxygenase channel in a conformation that is different than that observed for other COX-2-selective inhibitors, such as celecoxib, with no discernible penetration into the side pocket formed in COX-2 by the isoform-specific substitutions of I434V, H513R, and I523V. Instead, the methanesulfonamide moiety of NS-398 interacts with the side chain of Arg-120 at the opening of the cyclooxygenase channel, similar to that observed for acidic, nonselective NSAIDs such as indomethacin and flurbiprofen. Our structure validates inhibitor studies that identified Arg-120 as a molecular determinant for time-dependent inhibition of COX-2 by NS-398.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21843643      PMCID: PMC3185125          DOI: 10.1016/j.jsb.2011.07.019

Source DB:  PubMed          Journal:  J Struct Biol        ISSN: 1047-8477            Impact factor:   2.867


  42 in total

Review 1.  Cyclooxygenases: structural, cellular, and molecular biology.

Authors:  W L Smith; D L DeWitt; R M Garavito
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

Review 2.  Cox-2-selective inhibitors: the new super aspirins.

Authors:  D L DeWitt
Journal:  Mol Pharmacol       Date:  1999-04       Impact factor: 4.436

Review 3.  Structural and functional basis of cyclooxygenase inhibition.

Authors:  Anna L Blobaum; Lawrence J Marnett
Journal:  J Med Chem       Date:  2007-03-07       Impact factor: 7.446

4.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.

Authors:  R G Kurumbail; A M Stevens; J K Gierse; J J McDonald; R A Stegeman; J Y Pak; D Gildehaus; J M Miyashiro; T D Penning; K Seibert; P C Isakson; W C Stallings
Journal:  Nature       Date:  1996 Dec 19-26       Impact factor: 49.962

5.  The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs.

Authors:  G M Greig; D A Francis; J P Falgueyret; M Ouellet; M D Percival; P Roy; C Bayly; J A Mancini; G P O'Neill
Journal:  Mol Pharmacol       Date:  1997-11       Impact factor: 4.436

6.  Role of Val509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents.

Authors:  Q Guo; L H Wang; K H Ruan; R J Kulmacz
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

Review 7.  Cyclooxygenases: structural and functional insights.

Authors:  Carol A Rouzer; Lawrence J Marnett
Journal:  J Lipid Res       Date:  2008-10-23       Impact factor: 5.922

8.  NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.

Authors:  N Futaki; K Yoshikawa; Y Hamasaka; I Arai; S Higuchi; H Iizuka; S Otomo
Journal:  Gen Pharmacol       Date:  1993-01

9.  NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro.

Authors:  N Futaki; S Takahashi; M Yokoyama; I Arai; S Higuchi; S Otomo
Journal:  Prostaglandins       Date:  1994-01

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  12 in total

1.  Cyclooxygenase-2 catalysis and inhibition in lipid bilayer nanodiscs.

Authors:  Benjamin J Orlando; Daniel R McDougle; Michael J Lucido; Edward T Eng; Leigh Ann Graham; Claus Schneider; David L Stokes; Aditi Das; Michael G Malkowski
Journal:  Arch Biochem Biophys       Date:  2014-02-03       Impact factor: 4.013

2.  Cyclooxygenase enzyme activity does not impair respiratory motor plasticity after one night of intermittent hypoxia.

Authors:  Adrianne G Huxtable; Elizabeth Kopp; Brendan J Dougherty; Jyoti J Watters; Gordon S Mitchell
Journal:  Respir Physiol Neurobiol       Date:  2017-12-09       Impact factor: 1.931

3.  Pre-existent asymmetry in the human cyclooxygenase-2 sequence homodimer.

Authors:  Liang Dong; Narayan P Sharma; Brice J Jurban; William L Smith
Journal:  J Biol Chem       Date:  2013-08-16       Impact factor: 5.157

4.  The structure of ibuprofen bound to cyclooxygenase-2.

Authors:  Benjamin J Orlando; Michael J Lucido; Michael G Malkowski
Journal:  J Struct Biol       Date:  2014-11-25       Impact factor: 2.867

5.  Crystal structure of rofecoxib bound to human cyclooxygenase-2.

Authors:  Benjamin J Orlando; Michael G Malkowski
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2016-09-22       Impact factor: 1.056

6.  Fatty Acid Binding to the Allosteric Subunit of Cyclooxygenase-2 Relieves a Tonic Inhibition of the Catalytic Subunit.

Authors:  Liang Dong; Chong Yuan; Benjamin J Orlando; Michael G Malkowski; William L Smith
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

7.  Substrate-selective Inhibition of Cyclooxygeanse-2 by Fenamic Acid Derivatives Is Dependent on Peroxide Tone.

Authors:  Benjamin J Orlando; Michael G Malkowski
Journal:  J Biol Chem       Date:  2016-05-20       Impact factor: 5.157

8.  Regulation of rat intrapulmonary arterial tone by arachidonic acid and prostaglandin E2 during hypoxia.

Authors:  Gaoliang Yan; Qingjie Wang; Hui Shi; Yeshan Han; Genshan Ma; Chengchun Tang; Yuchun Gu
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

9.  Ginger components as new leads for the design and development of novel multi-targeted anti-Alzheimer's drugs: a computational investigation.

Authors:  Faizul Azam; Abdualrahman M Amer; Abdullah R Abulifa; Mustafa M Elzwawi
Journal:  Drug Des Devel Ther       Date:  2014-10-23       Impact factor: 4.162

10.  The COX-2-Selective Antagonist (NS-398) Inhibits Choroidal Neovascularization and Subretinal Fibrosis.

Authors:  Ruoshuang Zhang; Zheli Liu; Han Zhang; Yi Zhang; Dong Lin
Journal:  PLoS One       Date:  2016-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.